Oaktree Acquisition Corp. III Life Sciences (OACCW)

A warrant is a security that grants the holder the right — but not the obligation — to buy shares of the underlying company at a fixed strike price, exercisable within a defined window of time. The OACCW warrant is the warrant component of Oaktree Acquisition Corp. III Life Sciences, separated from the common-stock unit (OACCU). It is, in essence, a call option on the eventual merged company’s shares, issued directly by the SPAC rather than traded on an options exchange.

How SPAC warrants work

When a SPAC raises capital, it typically issues units that bundle one share of common stock with one warrant (or, sometimes, a fraction of a warrant). For accounting simplicity and trading convenience, sponsors often segregate the components. OACCU is the bundled unit; OACCW is the warrant alone. An investor can own the warrant separately and trade it independently of the stock. If an investor owns OACCU, they can typically elect to separate it into common stock and warrant, holding each as a distinct security.

The warrant has a fixed strike price — the price at which the holder can exercise (buy additional shares). This strike is typically set above the trust value per share at issuance. When the SPAC merges with a target, the warrant terms are adjusted (if necessary) to account for any outstanding claims, then the warrants remain outstanding under the merged company’s ownership structure. The warrant holder can typically exercise at any point after the merger closes and up to an expiration date — often five years after the merger.

Why investors buy warrants

A warrant is an embedded leverage play. If the merged company’s stock rises significantly above the strike price, the warrant becomes increasingly valuable. An investor who buys the warrant for a few dollars can control the right to buy shares at the strike price — and if the stock shoots higher, that right becomes extremely valuable. Conversely, if the merged company’s stock falls below the strike price or stays near it, the warrant becomes worthless as the holder would never exercise (why buy at the higher strike when the market price is lower?). This binary nature — potentially large upside, but a floor of zero — is what attracts speculative investors and why warrants trade at a meaningful discount to their intrinsic value when out of the money.

The economics of a SPAC warrant

SPAC sponsors designed the warrant structure to align incentives: if the merged company thrives, warrant holders benefit from the upside, which encourages them to hold through the merger and support the combined company’s post-merger strategy. However, the warrant structure also involves real economics that can matter to the merged company. If many warrants are exercised, the newly issued shares dilute existing shareholders. Merged companies sometimes buy back or retire outstanding warrants to reduce future dilution — a capital outlay that could otherwise be invested in operations.

The warrant also carries “redemption” features in some SPACs. Sponsors have the right to redeem (force the exercise or cancellation of) outstanding warrants under certain conditions, typically if the stock trades above a threshold for a defined period. This forces warrant holders to either exercise or lose their security, and has become controversial because it can pressure warrant holders to exercise at unfavorable terms.

What matters for OACCW holders

For an investor in the warrant, the central questions are the same as for any SPAC: Has a suitable target been identified? Does the merged company have a clear path to profitability or growth? The warrant holder benefits only if the merged company’s stock rises meaningfully above the strike price. The time value of the warrant — the value attributable purely to optionality before expiration — decays as the expiration date approaches, so warrant investors are taking both a directional bet (that the stock will rise) and a time bet (that it will rise before the warrant expires).

Because warrants are more volatile and binary than the underlying stock, they appeal to investors with higher risk tolerance and a bullish outlook on the life sciences sector and Oaktree’s ability to find a compelling target. The trade-off is total loss of capital if the merged company underperforms or the sector falls out of favor.